Cargando…

Therapeutic Apheresis in Metabolic Syndrome

BACKGROUND: The metabolic syndrome unites three pathologies of the person – obesity, arterial hypertension and diabetes. In recent years the progressing of such distribution covering from 2.5% to 3.8% of the population with increase twice each 10-15 years is noted. Even at maintenance of level of su...

Descripción completa

Detalles Bibliográficos
Autor principal: Voinov, V.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174637/
https://www.ncbi.nlm.nih.gov/pubmed/30369968
http://dx.doi.org/10.2174/1871522218666180608114536
_version_ 1783361315216031744
author Voinov, V.A.
author_facet Voinov, V.A.
author_sort Voinov, V.A.
collection PubMed
description BACKGROUND: The metabolic syndrome unites three pathologies of the person – obesity, arterial hypertension and diabetes. In recent years the progressing of such distribution covering from 2.5% to 3.8% of the population with increase twice each 10-15 years is noted. Even at maintenance of level of sugar at diabetes accumulation of the secondary metabolites breaking small vessels isn't excluded. At the same time many life-endangering complications develop. OBJECTIVE: To identify the possibilities of plasmapheresis in the prevention and treatment of complications of metabolic syndrome. METHOD: Analysis of the world literature data on complications of metabolic syndrome and methods of their treatment. RESULTS: At metabolic syndrome the frequency of strokes and myocardial infarctions there is twice more often than in population. For 5-9 years the general life expectancy decreases. Disorders of microcirculation at diabetes lead to a retinopathy with total loss of sight, a nephropathy from the outcome in a renal failure, to polyneuropathy and diabetic foot syndrome with high risk of high level amputations of the lower extremities. At the same time medicamentous therapy is not able to prevent such complications and almost only way of removal of these pathological metabolites is therapeutic apheresis, mainly the plasmapheresis. Data from our own studies confirm the effectiveness of such tactics. CONCLUSION: Plasmapheresis has to be applied not only to the correction of already critical conditions, but also to their prevention.
format Online
Article
Text
id pubmed-6174637
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-61746372018-10-26 Therapeutic Apheresis in Metabolic Syndrome Voinov, V.A. Immunol Endocr Metab Agents Med Chem Article BACKGROUND: The metabolic syndrome unites three pathologies of the person – obesity, arterial hypertension and diabetes. In recent years the progressing of such distribution covering from 2.5% to 3.8% of the population with increase twice each 10-15 years is noted. Even at maintenance of level of sugar at diabetes accumulation of the secondary metabolites breaking small vessels isn't excluded. At the same time many life-endangering complications develop. OBJECTIVE: To identify the possibilities of plasmapheresis in the prevention and treatment of complications of metabolic syndrome. METHOD: Analysis of the world literature data on complications of metabolic syndrome and methods of their treatment. RESULTS: At metabolic syndrome the frequency of strokes and myocardial infarctions there is twice more often than in population. For 5-9 years the general life expectancy decreases. Disorders of microcirculation at diabetes lead to a retinopathy with total loss of sight, a nephropathy from the outcome in a renal failure, to polyneuropathy and diabetic foot syndrome with high risk of high level amputations of the lower extremities. At the same time medicamentous therapy is not able to prevent such complications and almost only way of removal of these pathological metabolites is therapeutic apheresis, mainly the plasmapheresis. Data from our own studies confirm the effectiveness of such tactics. CONCLUSION: Plasmapheresis has to be applied not only to the correction of already critical conditions, but also to their prevention. Bentham Science Publishers 2018-05 2018-05 /pmc/articles/PMC6174637/ /pubmed/30369968 http://dx.doi.org/10.2174/1871522218666180608114536 Text en © 2018 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Voinov, V.A.
Therapeutic Apheresis in Metabolic Syndrome
title Therapeutic Apheresis in Metabolic Syndrome
title_full Therapeutic Apheresis in Metabolic Syndrome
title_fullStr Therapeutic Apheresis in Metabolic Syndrome
title_full_unstemmed Therapeutic Apheresis in Metabolic Syndrome
title_short Therapeutic Apheresis in Metabolic Syndrome
title_sort therapeutic apheresis in metabolic syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174637/
https://www.ncbi.nlm.nih.gov/pubmed/30369968
http://dx.doi.org/10.2174/1871522218666180608114536
work_keys_str_mv AT voinovva therapeuticapheresisinmetabolicsyndrome